Abstract: A method for impregnating an oxide fibre roving with a matrix of alumina and silica includes a introducing an oxide fibre roving into an impregnation bath, wherein the impregnation bath is prepared by sol-gel process and includes a silica precursor in the form of a hybrid polymeric sol, an alumina precursor in the form of a colloidal sol and ceramic particles.

Abstract: The invention relates to a method for manufacturing an optoelectronic component substrate (12) comprising a stack of layers, the method comprising a step of: preforming a substrate (12) comprising a face which has a pattern with at least one zone made of a first material and one zone made of a second material, the two materials being thermosetting or thermoplastic materials, the first material being an electrically conductive material and the second material being an electrically insulating material, and molding by compression the face of the substrate (12) with a face of a reference element (22) having a surface roughness less than or equal to 50 nanometers.

Abstract: Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2? reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation.

Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.

Abstract: A method for manufacturing an abradable layer and a substrate coated with this layer, may include: preparing a powder composition including at least ceramic particles and an inorganic filler having a lamellar crystallographic structure, the volume content of the inorganic filler in the powder composition being in a range of from 1 to 75%; compressing the powder composition; and sintering the powder composition thus compressed in order to obtain the abradable layer.

Abstract: A method for producing a permanent or soft magnet including the following steps: a) providing: a solution containing a solvent in which are dispersed a set of objects which possess a permanent magnetic moment; a substrate on which are fixed to the surface or within a cavity that it may have, a 1st pad and a 2nd pad, said 1st pad includes a face facing and parallel to a face that the 2nd pad includes; b) the solution is deposited on the surface of the substrate or, as the case may be, within its cavity; c) the substrate is placed in a magnetic field so that the set of objects are grouped together between the face of the 1st pad and the face of the 2nd pad so as to form a permanent magnet.

Abstract: The present invention relates to a vascular stent, deployed or non-deployed, the surface of which is coated by a film comprising at least one protein, to a process for coating of the surface of a vascular stent with a film comprising at least one protein and to a device for carrying out the process according to the invention.

Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.

Abstract: The invention relates to the field of modified Escherichia coli strain Nissle 1917 (EcN) and its use for treating gastro-intestinal disorders. The invention is based on the study of the mechanisms implicated in the probiotic properties of the Escherichia coli strain Nissle 1917 (EcN). This study has allowed the inventors to decouple the probiotic activity of EcN from its genotoxic activity by demonstrating that EcN ClbP protein, the enzyme that activates the genotoxin colibactin, is also required for the siderophore-microcins activity of probiotic EcN, but interestingly, not its enzymatic domain that cleaves precolibactin to form active colibactin.

Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. However, the mutational pattern of PI3K pathway or its level of expression is not sufficient to predict the sensitivity to PI3K inhibitors. By identifying for the first time a phosphopeptide that predict the sensitivity to p110? and/or p110? inhibitors, the inventors provide insight in how to handle heterogeneity of PI3K expression patterns in tumoral samples for the choice of available PI3K-targetting drugs. Accordingly, the present relates to a phosphopeptide characterized by the amino acid sequence as set forth in SEQ ID NO:1 (PGTPSDHQSQEASQFER) wherein the threonine residue at position 3 is phosphorylated.

Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.

Abstract: A method for preparing an organic/inorganic hybrid composition including mineral nanoparticles functionalized by at least one molecule chosen from colored charged organic molecules, this method including providing a solution (a) of at least one colored charged organic molecule, providing a suspension (b) of non-swelling phyllosilicate nanoparticles, contacting the solution (a) and the suspension (b), the non-swelling phyllosilicate nanoparticles having a thickness of 1 nm to 100 nm, and a larger dimension of 10 nm to 10 ?m. A composition of organic/inorganic hybrid colored nanoparticles obtained by this method is also disclosed.

Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.

Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a prolonged activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.

Abstract: The present invention relates to methods and kits for detection protein-protein interactions.

Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.

Abstract: The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the ?I7I-I85cit peptide of amino acid sequence VDIDIKIX1SCX2GSCS (SEQ ID NO: 8) wherein X1 and X2 each represent a citmllyl residue, —the ?62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X1 and X2 each represent a citmllyl residue.

Abstract: Vaccines for preventing or treating diabetes, obesity and complications thereof are provided. The vaccines comprise at least one active agent such as attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a cDNA from Porphyromonas gingivalis.

Abstract: A method for preparing a composition including mineral particles functionalized by at least one organic group and having a specific surface defined according to the BET method greater than 500 m2/g, involves: —choosing a phyllosilicate composition, including mineral particles having a thickness of less than 100 nm, a largest dimension of less than 10 ?m and belonging to the family of lamellar silicates; —choosing at least one functionalizing agent, from the group formed from the oxysilanes and oxygermanes having at least one organic group, —bringing the phyllosilicate composition into contact with a functionalizing solution including the functionalizing agent, so as to obtain a phyllosilicate composition including mineral particles functionalized by the organic group, while choosing the organic group from the group formed from the cationic heteroaryl groups, the quaternary ammonium groups and the salts of same. The phyllosilicate composition obtained by the method is also described.